2017年高危黑色素瘤辅助治疗全面革新及其对分期和管理的影响
III期试验显示纳武利尤单抗对比伊匹木单抗在完全切除的IIIB/C-IV期患者及达拉非尼联合曲美替尼在BRAF突变III期患者中取得显著结局,表明晚期黑色素瘤有效药物在辅助治疗中同样高效。2017年结果改变实践,终止干扰素和伊匹木单抗的使用,并因MSLT-2试验导致完成淋巴结清扫减少,需紧急讨论如何保证最佳分期信息。
要点
- 纳武利尤单抗和达拉非尼联合曲美替尼在辅助治疗中高效,毒性谱与晚期经验一致。
- 2017年结果改变实践,终止干扰素和伊匹木单抗的使用。
- MSLT-2试验导致完成淋巴结清扫减少,需紧急讨论保证最佳分期信息。
核心结论
- 晚期黑色素瘤的有效治疗在辅助治疗中同样高度有效。
- 2017年结果改变实践,终止干扰素和伊匹木单抗的使用。
- 完成淋巴结清扫减少导致最佳预后信息缺乏,需紧急讨论如何保证最佳分期信息。
研究设计与样本
- 涉及纳武利尤单抗对比伊匹木单抗的III期试验(完全切除的IIIB/C-IV期患者)。
- 涉及达拉非尼联合曲美替尼的III期试验(BRAF突变III期患者)。
- 提及EORTC 1325试验比较帕博利珠单抗对比安慰剂,将于2018年初完成。
- 提及MSLT-2试验结果。
主要发现
- 纳武利尤单抗对比伊匹木单抗在完全切除的IIIB/C-IV期患者中取得显著结局。
- 达拉非尼联合曲美替尼在BRAF突变III期患者中取得显著结局。
- 2016年证实辅助高剂量伊匹木单抗的总生存获益。
- 毒性谱与晚期黑色素瘤经验一致:抗PD1药物和达拉非尼联合曲美替尼有利,伊匹木单抗有问题。
- 前哨淋巴结阳性IIIA/B期患者预后极不均一,5年生存率从90%到40%不等,主要取决于完成淋巴结清扫识别的阳性淋巴结数量。
关键数值与推荐
- 在仅能获取干扰素的国家,其使用可基于近期发表的个体患者数据荟萃分析限制于溃疡性黑色素瘤患者。
临床怎么用
- 2017年结果改变实践,终止干扰素和伊匹木单抗的使用。
- 在仅能获取干扰素的国家,其使用可限制于溃疡性黑色素瘤患者。
- 完成淋巴结清扫将急剧减少,需紧急讨论如何保证最佳分期信息。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The spectacular outcomes of the phase III trials regarding nivolumab versus ipilimumab in fully resected stage IIIB/C-IV and of the combination of dabrafenib (D) plus trametinib (T) in BRAF-mutant stage III patients demonstrate that effective treatments in advanced melanoma are also highly effective in the adjuvant setting. In 2016, an overall survival benefit with adjuvant high-dose ipilimumab was demonstrated, and the European Organisation for Research and Treatment of Cancer trial 1325 comparing pembrolizumab versus placebo will complete the picture in the early 2018. Toxicity profiles are in line with the experience in advanced melanoma, i.e. favourable for the anti-PD1 agents and for D + T and problematic for ipilimumab. The 2017 outcomes are practice changing and put an end to the use of interferon (IFN) and ipilimumab. In countries with only access to IFN, its use can be restricted to patients with ulcerated melanoma, based on the individual patient data meta-analysis recently published. Because of the results of the Melanoma Sentinel Lymph node Trial-2 (MSLT-2) trial, completion lymph node dissection (CLND) will decrease sharply, leading to a lack of optimal prognostic information. Prognosis in sentinel node-positive stage IIIA/B patients is extremely heterogeneous with 5-year survival rates varying from 90% to 40% and depends mostly on the number of positive nodes identified by CLND. This information is crucial for clinical decision-making. How to guarantee optimal staging information needs to be discussed urgently. Further improvements of adjuvant therapies will have to address all these questions as well as the exploration of neoadjuvant use of active drugs and combination approaches. Important paradigm shifts in the management of high-risk melanoma patients are upon us.
引用
- Eggermont AMM, Dummer R. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients. Eur J Cancer. 2017. PMID: 28968566. doi:10.1016/j.ejca.2017.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。